EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Big Pharma Split's Enterprise Value is C$12.77 Mil.
Big Pharma Split's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was C$-0.89 Mil. Therefore, Big Pharma Split's EV-to-FCF for today is -14.33.
The historical rank and industry rank for Big Pharma Split's EV-to-FCF or its related term are showing as below:
TSX:PRM'
s EV-to-FCF Range Over the Past 10 Years
Min: -14.46 Med: 1.81 Max: 20.26
Current: -14.33
During the past 9 years, the highest EV-to-FCF of Big Pharma Split was 20.26. The lowest was -14.46. And the median was 1.81.
TSX:PRM's EV-to-FCF is not ranked
in the Asset Management industry.
Industry Median: 14.5
vs TSX:PRM: -14.33
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Big Pharma Split's PE Ratio (TTM) for today is calculated as:
Big Pharma Split's share price for today is C$11.61.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Big Pharma Split's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was C$3.338.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Big Pharma Split EV-to-FCF Related Terms
Big Pharma Split EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Big Pharma Split's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, Big Pharma Split's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Big Pharma Split EV-to-FCF vs Asset Management Industry
For the Asset Management industry and Financial Services sector, Big Pharma Split's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Big Pharma Split's EV-to-FCF falls into.
Big Pharma Split's current Enterprise Value is C$12.77 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Big Pharma Split's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was C$-0.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Big Pharma Split (TSX:PRM) has a EV-to-FCF of -14.33 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Big Pharma Split and its competitors.
Is Big Pharma Split's EV-to-FCF too high?
Big Pharma Split's current EV-to-FCF is -14.33. Overall, Big Pharma Split has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Big Pharma Split's EV-to-FCF compare to BLK and BX?
Big Pharma Split's EV-to-FCF of -14.33 can be compared against companies in the Asset Management industry. The industry median EV-to-FCF is 14.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for an Asset Management company?
The median EV-to-FCF among Asset Management companies is 14.50, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Big Pharma Split and its competitors. For the Asset Management industry, the median EV-to-FCF is 14.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Big Pharma Split's current EV-to-FCF is -14.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Big Pharma Split stock overvalued right now?
Big Pharma Split (TSX:PRM) has a current EV-to-FCF of -14.33. The stock's GF Value™ is C$1.80, compared to a current price of C$11.61 — trading 545% above its estimated fair value. The current EV-to-FCF is -14.33. Big Pharma Split's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Big Pharma Split (TSX:PRM), the current EV-to-FCF is -14.33 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Big Pharma Split (TSX:PRM) Overvalued in 2026?
Based on GuruFocus' analysis, Big Pharma Split stock appears to be overvalued.
The current stock price of C$11.61 is trading 545% above its estimated GF Value™ of C$1.80.
Key valuation signals for TSX:PRM:
EV-to-FCF: -14.33
GF Value™: C$1.80 vs. price of C$11.61 (545% above fair value)
No single metric tells the full story. See the TSX:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Big Pharma Split Corp is a closed end mutual fund corporation. The investment objective of the company is to provide shareholders with fixed cumulative preferential quarterly cash distributions and regular monthly cash distributions. The company has a presence in the United States, France, and the United Kingdom.
7GF Score
Get the complete analysis for TSX:PRM
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:PRM has been successfully added to your 
